| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LBW242 | CCLE | pan-cancer | AAC | -0.03 | 0.5 |
| mRNA | semagacestat | CTRPv2 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | oligomycin a | CTRPv2 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.028 | 0.5 |
| mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.02 | 0.5 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.021 | 0.5 |
| mRNA | SNX-2112 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.5 |